WallStreetZenWallStreetZen

NASDAQ: PACB
Pacific Biosciences Of California Inc Stock

$2.18+0.56 (+34.57%)
Updated Jul 16, 2024
PACB Price
$2.18
Fair Value Price
N/A
Market Cap
$592.37M
52 Week Low
$1.16
52 Week High
$14.55
P/E
-1.91x
P/B
0.91x
P/S
5.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$200.43M
Earnings
-$296.90M
Gross Margin
27.1%
Operating Margin
-146.7%
Profit Margin
-148.1%
Debt to Equity
1.57
Operating Cash Flow
-$240M
Beta
1.84
Next Earnings
Jul 31, 2024
Ex-Dividend
N/A
Next Dividend
N/A

PACB Overview

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Zen Score

Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PACB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

PACB is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PACB is good value based on its book value relative to its share price (0.91x), compared to the US Medical Devices industry average (3.89x)
P/B vs Industry Valuation
PACB is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PACB due diligence checks available for Premium users.

Be the first to know about important PACB news, forecast changes, insider trades & much more!

PACB News

Valuation

PACB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.91x
Industry
29.86x
Market
31.71x

PACB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.91x
Industry
3.89x
PACB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

PACB's financial health

Profit margin

Revenue
$38.8M
Net Income
-$78.2M
Profit Margin
-201.4%
PACB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PACB's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.7B
Liabilities
$1.0B
Debt to equity
1.57
PACB's short-term assets ($677.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PACB's long-term liabilities ($947.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PACB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PACB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$75.7M
Investing
-$34.1M
Financing
$6.6M
PACB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

PACB vs Medical Device Stocks

TickerMarket Cap1d %P/EP/B
PACB$592.37M+34.26%-1.91x0.91x
IRMD$592.68M+1.83%32.96x7.79x
SRDX$600.49M+0.33%43.86x4.84x
VREX$602.40M+4.22%14.48x1.05x
OFIX$605.72M+2.09%-4.78x1.06x

Pacific Biosciences Of California Stock FAQ

What is Pacific Biosciences Of California's quote symbol?

(NASDAQ: PACB) Pacific Biosciences Of California trades on the NASDAQ under the ticker symbol PACB. Pacific Biosciences Of California stock quotes can also be displayed as NASDAQ: PACB.

If you're new to stock investing, here's how to buy Pacific Biosciences Of California stock.

What is the 52 week high and low for Pacific Biosciences Of California (NASDAQ: PACB)?

(NASDAQ: PACB) Pacific Biosciences Of California's 52-week high was $14.55, and its 52-week low was $1.16. It is currently -85.05% from its 52-week high and 87.5% from its 52-week low.

How much is Pacific Biosciences Of California stock worth today?

(NASDAQ: PACB) Pacific Biosciences Of California currently has 272,355,892 outstanding shares. With Pacific Biosciences Of California stock trading at $2.18 per share, the total value of Pacific Biosciences Of California stock (market capitalization) is $592.37M.

Pacific Biosciences Of California stock was originally listed at a price of $16.44 in Oct 27, 2010. If you had invested in Pacific Biosciences Of California stock at $16.44, your return over the last 13 years would have been -86.77%, for an annualized return of -14.41% (not including any dividends or dividend reinvestments).

How much is Pacific Biosciences Of California's stock price per share?

(NASDAQ: PACB) Pacific Biosciences Of California stock price per share is $2.18 today (as of Jul 16, 2024).

What is Pacific Biosciences Of California's Market Cap?

(NASDAQ: PACB) Pacific Biosciences Of California's market cap is $592.37M, as of Jul 17, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Pacific Biosciences Of California's market cap is calculated by multiplying PACB's current stock price of $2.18 by PACB's total outstanding shares of 272,355,892.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.